



September 28, 2017

Nasdaq Welcomes Nightstar Therapeutics Nightstar plc (Nasdaq: NITE) to The Nasdaq Stock Market

NEW YORK, Sept. 28, 2017 (GLOBE NEWSWIRE) -- Nightstar Therapeutics plc (Nasdaq:NITE), a leading clinical-stage gene therapy company, rang the closing bell at the Nasdaq MarketSite in Times Square today in celebration of its initial public offering (IPO) on The Nasdaq Stock Market.

Photos accompanying this announcement are available at

<http://www.globenewswire.com/NewsRoom/AttachmentNg/f735cbc8-df61-417e-9a3a-3dee84c8a5ed>

<http://www.globenewswire.com/NewsRoom/AttachmentNg/ea0abfbd-e1c2-43e7-9091-8d8c86fb60ce>

Nightstar Therapeutics focuses on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases that would otherwise progress to blindness. Through their expertise in ophthalmology, gene therapy and drug development, they are developing a pipeline of proprietary product candidates that are designed to substantially modify or halt the progression of inherited retinal diseases for which there are no currently approved treatments.


"Nightstar Therapeutics continues to innovate in life changing treatments," said Nelson Griggs, President of the Nasdaq Stock Exchange, "We are extremely proud to partner with them as they continue to break barriers in the health care sector as a public company."

The information contained above is provided for informational and educational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. Information about the company is provided by the company or comes from the company's public filings and is not independently verified by Nasdaq. Neither Nasdaq nor any of its affiliates makes any recommendation to buy or sell any security or any representation about the financial condition of any company. Statements regarding Nasdaq-listed companies are not guarantees of future performance. Actual results may differ materially from those expressed or implied. Past performance is not indicative of future results. Investors should undertake their own due diligence and carefully evaluate companies before investing. ADVICE FROM A SECURITIES PROFESSIONAL IS STRONGLY ADVISED.

About Nasdaq

Nasdaq (Nasdaq:NDAQ) is a leading global provider of trading, clearing, exchange technology, listing, information and public company services. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 90 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to approximately 3,900 total listings with a market value of approximately \$12 trillion. To learn more, visit: <http://business.nasdaq.com>.

Media Relations Contacts:

 [Nightstar Therapeutics \(Nasdaq: NITE\) Rings The Nasdaq Stock Market Closing Bell in Celebration of Its IPO](#)

Nightstar Therapeutics plc (Nasdaq: NITE), a leading clinical-stage gene therapy company focused on novel one-time treatments for patients suffering from rare inherited retinal diseases that would otherwise progress to blindness, visits the Nasdaq MarketSite in Times Square in celebration of its initial public offering (IPO).

 [David Fellows, Chief Executive Officer and Board Member, rings the Nasdaq Closing Bell](#)

Nightstar Therapeutics (Nasdaq: NITE) Rings The Nasdaq Stock Market Closing Bell in Celebration of Its IPO.

Stephanie Lowenthal
(646) 441-5073
Stephanie.Lowenthal@nasdaq.com

Emily Pan
(646) 441-5120
emily.pan@nasdaq.com

- NDAQ -

 Primary Logo

Source: NASDAQ, Inc.

News Provided by Acquire Media